Status:
WITHDRAWN
a Study in Subjects With Otoferlin Mutation-related Hearing Loss Using RNA Base-eDiting Therapy(SOUND)
Lead Sponsor:
HuidaGene Therapeutics Co., Ltd.
Collaborating Sponsors:
Eye & ENT Hospital of Fudan University
Conditions:
Congenital Hearing Loss
Eligibility:
All Genders
1-16 years
Phase:
EARLY_PHASE1
Brief Summary
The purpose of the study is to determine whether HG205 as CRISPR/Cas13 RNA base-editing therapy is safe and effective for the treatment of hearing loss caused by p.Q829X mutation in OTOF gene.
Eligibility Criteria
Inclusion
- Male or females between 1 and 16 years of age at the time the subject/parent/legal guardian signs the informed consent form.
- Willing to adhere to the protocol as evidenced by written informed consent or parental permission and subject assent.
- Molecular diagnosis of biallelic mutations in the OTOF gene with at least one mutation being p.Q829X through collected blood samples at screening;
- Based on auditory brainstem response (ABR), clinically diagnosed sensorineural hearing loss (SNHL) with the following hearing thresholds: severe (65 dB ≤ hearing threshold \< 80 dB) or profound (80 dB ≤ hearing threshold \< 95 dB) or complete (hearing threshold ≥ 95 dB) hearing loss in both ears.
- Acceptable hematology, clinical chemistry, and urine laboratory parameters.
Exclusion
- Pre-existing other hearing-loss conditions that would preclude the planned surgery or interfere with the interpretation of study endpoints or complications of surgery.
- Presence of cochlear implants in the study ear.
- Complicating systemic diseases or clinically significant abnormal baseline laboratory values.
- Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter hearing function.
- Prior participation in clinical study with an investigational drug within the past six months.
- Prior gene therapy treatments.
- Any condition which leads the investigator to believe that the participant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for participation.
Key Trial Info
Start Date :
March 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 8 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06025032
Start Date
March 30 2023
End Date
April 8 2025
Last Update
April 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye & ENT Hospital of Fudan University
Shanghai, China